Alcohol industry rolls into fast-growing cannabis market
By Jennifer Kaplan
January 6, 2018
Constellation Brands isn’t quite sure whether legal cannabis is friend or foe to the alcohol industry. Either way, it wants in.
The maker of Robert Mondavi wine, Corona beer and Svedka vodka is still waiting for the chips to fall into place after entering the up-and-coming (and turbulent) marijuana industry last year by taking a minority stake in Canada’s Canopy Growth.
The rapid increase of the cannabis market has caused analysts to question whether drinkers could shift their spending to smoking as prohibitions on the plant’s recreational use are removed.
“It’s probably not worth getting in a big debate right now about whether it’s cannibalistic or complementary,” Constellation chief executive Rob Sands said on a call with analysts today.
“There’s just not enough information to really say how that’s going to effect beverage alcohol generally moving forward. What we do know is it’s going to be a big market worldwide.”
The New York-based company’s cannabis investment is being closely watched since it’s the first time that big alcohol has entered the so-called Green Rush.
The scrutiny only intensified this week after US Attorney General Jeff Sessions rescinded the Obama-era policy that let federal prosecutors look the other way while states set up their own markets for marijuana. The announcement followed California’s launch of a legal marketplace on January 1.
For now, Sands says Constellation and Canopy are developing a non-alcoholic cannabis beverage for release when Canada’s government legalises pot drinks, expected in 2019.
Constellation could certainly use a new growth source. Its sales of wine and spirits have persistently fallen, and investors are starting to notice.
Shares of the company fell as much as 4.2 per cent to US$216.25 today, the most intraday in more than 10 months, after it reported declines in volume and sales for wine and spirits.
Constellation has ridden the strength of its imported Mexican beer to become an investor darling – 15 analysts recommend buying the shares and none recommend selling them – but even growth in that category was less than what some had expected.
Bloomberg